Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

被引：1
|
作者：
Mellbin, Linda G. [1 ,2 ]
Bhatt, Deepak L. [3 ]
David, Jens-Peter [4 ]
Ekstrom, Kathrine [4 ]
Petrie, Mark C. [5 ]
Rasmussen, Soren [4 ]
Vilsboll, Tina [6 ]
机构：
[1] Karolinska Inst, Dept Med Solna, Eugeniavagen 27, S-17164 Solna, Stockholm, Sweden
[2] Karolinska Univ Hosp, Heart Vasc & Neuro Theme, K2 Med,K2 Kardio Pernow J, S-17177 Solna, Stockholm, Sweden
[3] Mt Sinai Fuster Heart Hosp, Icahn Sch Med Mt Sinai, New York, NY USA
[4] Novo Nord A S, Soborg, Denmark
[5] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow City, Scotland
[6] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 15期
关键词：
Cardiovascular outcomes trial; Glucagon-like peptide-1 receptor agonist; HbA(1c); Major adverse cardiovascular events; PIONEER; 6; Post hoc analysis; Semaglutide; SUSTAIN; Type; 2; diabetes;
D O I：
10.1093/eurheartj/ehae028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1371 / 1374
页数：4
相关论文
共 50 条
  • [31] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Mansoor Husain
    Agostino Consoli
    Alessandra De Remigis
    Anna Sina Pettersson Meyer
    Søren Rasmussen
    Stephen Bain
    Cardiovascular Diabetology, 21
  • [32] Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials
    Verma, S.
    Bain, S. C.
    Bhatt, D. L.
    Leiter, L. A.
    Mazer, C. D.
    McGuire, D. K.
    Pratley, R.
    Zinman, B.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Buse, J. B.
    DIABETOLOGIA, 2019, 62 : S560 - S560
  • [33] Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
    Strain, W. David
    Frenkel, Ofir
    James, Martin A.
    Leiter, Lawrence A.
    Rasmussen, Soren
    Rothwell, Peter M.
    Ripa, Maria Sejersten
    Truelsen, Thomas C.
    Husain, Mansoor
    STROKE, 2022, 53 (09) : 2749 - 2757
  • [34] Relationship of baseline HbA1c and HbA1c reduction following insulin therapy in Type 2 diabetes
    Giugliano, D.
    Esposito, K.
    DIABETIC MEDICINE, 2011, 28 (02) : 247 - 247
  • [35] Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials
    Giugliano, D.
    Maiorino, M.
    Bellastella, G.
    Chiodini, P.
    Esposito, K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (05) : 602 - 612
  • [36] SEMAGLUTIDE REDUCED CARDIOVASCULAR EVENTS REGARDLESS OF METFORMIN USE: A POST HOC EXPLORATORY SUBGROUP ANALYSIS OF SUSTAIN 6 AND PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina
    Rasmussen, Soren
    Bain, Stephen
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1604 - 1604
  • [37] THE IMPACT OF BASELINE HBA1C AND HBA1C TRAJECTORIES ON TIME TO THERAPY ESCALATION IN TYPE 2 DIABETES MELLITUS
    McEwan, P.
    Foos, V
    Larnotte, M.
    VALUE IN HEALTH, 2015, 18 (07) : A698 - A698
  • [38] In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
    Gandhi, Gunjan Y.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (11) : JC127 - JC127
  • [39] Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
    Bain, Stephen C.
    Mosenzon, Ofri
    Arechavaleta, Rosario
    Bogdanski, Pawel
    Comlekci, Abdurrahman
    Consoli, Agostino
    Deerochanawong, Chaicharn
    Dungan, Kathleen
    Faingold, Maria C.
    Farkouh, Michael E.
    Franco, Denise R.
    Gram, Jeppe
    Guja, Cristian
    Joshi, Pankaj
    Malek, Rachid
    Merino-Torres, Juan F.
    Nauck, Michael A.
    Pedersen, Sue D.
    Sheu, Wayne H. -H.
    Silver, Robert J.
    Tack, Cees J.
    Tandon, Nikhil
    Jeppesen, Ole K.
    Strange, Mette
    Thomsen, Mette
    Husain, Mansoor
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 499 - 508
  • [40] Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
    Tuttle, Katherine R.
    Bosch-Traberg, Heidrun
    Cherney, David Z. I.
    Hadjadj, Samy
    Lawson, Jack
    Mosenzon, Ofri
    Rasmussen, Soren
    Bain, Stephen C.
    KIDNEY INTERNATIONAL, 2023, 103 (04) : 772 - 781
12345